| Ebrahim Versi |
Ebrahim Versi is a businessperson who founded DMK Pharmaceuticals Corp. and Dignify Therapeutics LLC and who has been at the head of 5 different companies. Currently, Dr. Versi holds the position of Chairman & Chief Executive Officer of Adamis Pharmaceuticals Corp., Chairman & Chief Executive Officer for DMK Pharmaceuticals Corp. (a subsidiary of Adamis Pharmaceuticals Corp.), Chief Executive Officer & Director at Urigen Pharmaceuticals, Inc. and President for Versi Group LLC. Ebrahim Versi is also Member of Royal College of Obstetricians & Gynaecologists.
Dr. Versi previously was President for Veris Consulting, Inc., Chief Medical Officer of Mt. Cook Pharma, Inc., Director-Urology & Health at Pfizer Inc., Senior Vice President-Development at Plethora Solutions Plc, Vice President-Medical Affairs of Yamanouchi Pharma America, Inc., Professor at Harvard University and Principal at The Brigham & Women's Hospital, Inc.
Ebrahim Versi received an undergraduate degree and a doctorate from the University of Oxford and a doctorate from the University of Cambridge. |
| Ronald B. Moss |
Presently, Ronald B. Moss holds the position of Chief Medical Officer of Adamis Pharmaceuticals Corp. Dr. Moss is also on the board of Biosortia Pharmaceuticals, Inc.
In his past career Dr. Moss occupied the position of President & Chief Executive Officer for Orchestra Therapeutics, Inc., President & Chief Executive Officer for Ansun Biopharma, Inc., Vice President-Medical Affairs for Telos Pharmaceuticals LLC, Assistant Medical Director at Immunization Products Ltd., Senior Director-Worldwide Regulatory Affairs at Merck & Co., Inc., Vice President-Clinical Development at Vical, Inc. and Clinical Associate-Allergy & Clinical Immunology at National Institutes of Health.
Ronald B. Moss received an undergraduate degree from Stony Brook University, a doctorate from Chicago Medical School and a doctorate from Rosalind Franklin University of Medicine & Science. |
| Richard C. Williams |
Founder of Conner-Thoele Ltd., Richard C. Williams is a businessperson who has been the head of 8 different companies and is Chairman of Adamis Pharmaceuticals Corp. and President of Conner-Thoele Ltd. He is also on the board of CereHealth Corp.
In the past Mr. Williams held the position of Chairman at ISTA Pharmaceuticals, Inc., Chairman for King Pharmaceuticals Research & Development, Inc., Chairman & Acting Chief Executive Officer at Cellegy Pharmaceuticals, Inc., Co-Chairman for Abbott Molecular, Inc., Chairman for Adamis Pharmaceuticals Corp., Chairman at Vysis, Inc. and Director & Vice Chairman-Strategic Planning at KP Pharmaceuticals LLC.
Richard C. Williams received an undergraduate degree from DePauw University and an MBA from The Wharton School of the University of Pennsylvania. |
| David C. Benedicto |
Currently, David C. Benedicto holds the position of Chief Financial Officer at Adamis Pharmaceuticals Corp.
He previously occupied the position of Controller at HERC Products, Inc., Controller for BAE Systems, Inc. and Accounting Manager at Trius Therapeutics, Inc.
David C. Benedicto received an undergraduate degree from the University of St. La Salle and an MBA from the University of Redlands. |
| David J. Marguglio |
David J. Marguglio founded Adamis Pharmaceuticals Corp. and Adamis Pharmaceuticals Corp. Presently, he is President, CFO, COO & Secretary at Adamis Pharmaceuticals Corp.
In the past he was Vice President for Merrill Lynch & Co., Inc., Vice President at Citigroup Global Markets, Inc. and VP-Business Development & Investor Relations at Adamis Pharmaceuticals Corp.
Mr. Marguglio received an undergraduate degree from Hankamer School of Business. |
| Vickie W. Reed |
Vickie W. Reed is on the board of Evoke Pharma, Inc. and Adamis Pharmaceuticals Corp. In the past Ms. Reed occupied the position of Senior VP, Chief Financial & Accounting Officer at Mirati Therapeutics, Inc., Senior Director-Finance & Controller at Zogenix, Inc. and Head-Corporate Accounting at Amylin Pharmaceuticals, Inc.
Vickie W. Reed received an undergraduate degree from The University of Colorado. |
| Howard C. Birndorf |
Founder of 8 different companies, among them: Gen-Probe, Inc., Ligand Pharmaceuticals, Inc. and Ngen, Inc. Howard C. Birndorf is an entrepreneur and businessperson who has been the head of 5 different companies and is Chairman of Ha Cell Technology, Inc. and Chairman for FasTraq, Inc. Dr. Birndorf is also on the board of Adamis Pharmaceuticals Corp. and Principal at BCM Benefits LLC (he founded the company in 2010).
Howard C. Birndorf previously was Chairman & Chief Executive Officer for Ngen, Inc. (he founded the company in 1991), President of Birndorf Technology Development, Director & Executive Vice President at Gen-Probe, Inc. (he founded the company), Co-Chairman at The Coalition for 21st Century Medicine (he founded the company), Chairman-Emeritus at Ligand Pharmaceuticals, Inc. and Director at IDEC Pharmaceuticals Corp.
Howard C. Birndorf received an undergraduate degree from Oakland University (Michigan) and a graduate degree from Wayne State University (Michigan). |
| Meera J. Desai |
Founder of Karana Biotech LLC, Meera J. Desai is on the board of Adamis Pharmaceuticals Corp. and Nielsen BioSciences, Inc. and Associate Director-Pharmaceutical Development at Novartis Pharmaceuticals Corp. and Managing Director at Karana Biotech LLC.
Dr. Desai previously occupied the position of Program Manager at Nektar Therapeutics, Senior Director-Corporate Development at AcelRx Pharmaceuticals, Inc. and Program Manager at ALZA Corp.
She received an undergraduate degree from Drew University and a doctorate from Iowa State University. |
